This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Malignant neoplasms of independent (primary) multiple sites독립된 (원발성) 다발 부위의 악성신생물 (다발성원발암)

A. Classification codesICD-10: C97 | No separate subcodes; the ICD-10 code of each primary site is recorded as an additional code | Special Copayment Reduction V193 (copayment 5%, for 5 years from registration — criteria of each corresponding cancer apply)
B. SynonymsMultiple primary cancers (MPC), double primary cancer, triple primary cancer, synchronous MPC, metachronous MPC, multiple primary malignant tumors
C. Adult onsetVery high — multiple primary cancers occur mainly in cancer survivors (10-15% of all cancer patients), with incidence rising sharply in older adults; frequency is trending upward along with the growing number of survivors as cancer treatment advances
Contents 1. History · 2. Causes · 3. Genetics · 4. Epidemiology · 5. Pathophysiology · 6. Symptoms · 7. Signs · 8. Screening · 9. Diagnosis · 10. Treatment · 11. Prognosis · 12. Prevention · 13. References

1. History

The concept of multiple primary cancers (MPC) first began to be described in 1889, when Billroth reported a case of two independent malignancies arising in one patient. In 1932, Warren and Gates systematically reviewed 1259 cases of multiple primary cancers and proposed criteria for determining primary cancers, laying the foundation for modern MPC research.

As cancer registration systems developed worldwide after 1960, epidemiologic data on MPC began to accumulate. The US SEER (Surveillance, Epidemiology, and End Results) program, the Swedish Cancer Registry, the Danish Cancer Registry and others made large cohort studies possible. In 1977, Schlachtenhauff and Schlesinger proposed standard definition criteria for multiple primary cancers, and after subsequent revisions, the criteria of the International Agency for Research on Cancer (IARC) and the North American Association of Central Cancer Registries (NAACCR) are currently used.

In the late 20th century, interest in MPC research grew greatly as therapy-related second primary cancers caused by radiotherapy and chemotherapy increased. Hereditary predispositions (Lynch syndrome, BRCA1/2, Li-Fraumeni syndrome, etc.) were found to be strongly associated with special subtypes of MPC, and since the 2000s, advances in next-generation genomic analysis have made genomic analysis across multiple independent primary cancers possible. In Korea, MPC incidence trends are continuously analyzed through the National Cancer Center cancer survivor database and the Korea Central Cancer Registry.

2. Causes

Endogenous (genetic) and exogenous (environmental) factors are intricately intertwined in the development of multiple primary cancers. Genetic predisposition forms the most important single group of risk factors. Lynch syndrome: germline mutations of the MLH1, MSH2, MSH6 and PMS2 genes, in which cancers arise at various sites besides the colon—endometrium, stomach, ovary, ureter, brain and others—showing a typical MPC pattern. BRCA1/2 germline mutations: the risks of breast and ovarian cancer are both increased, and a pattern of one of these cancers developing after treatment of the other is common. Li-Fraumeni syndrome (TP53 germline), PTEN hamartoma syndrome (PTEN germline) (breast, thyroid and endometrial cancer), FAP/APC germline (colorectal cancer, duodenal papillary cancer, brain tumors) and others are also genetic syndromes strongly associated with MPC.

MPC due to prior cancer treatment: after radiotherapy, secondary radiation-induced cancers develop within the irradiation field 10-20 years later (osteosarcoma, breast cancer, lung cancer, etc.). Therapy-related AML/MDS due to alkylating agents and topoisomerase II inhibitors. Shared risk factors: smoking is a risk factor for many cancers, including lung, head and neck, bladder, esophageal and pancreatic cancer, and an MPC pattern in which a smoking-related cancer arises at another site after treatment of one cancer is common. Alcohol is a shared risk factor for head and neck, esophageal and liver cancer. Chronic infections (HPV, HBV, H. pylori) are also shared risk factors. Immunosuppression: in patients using immunosuppressants after organ transplantation, skin cancer, lymphoma and other cancers develop simultaneously or sequentially.

3. Genetics

The genetics of multiple primary cancers can be divided mainly into germline mutations associated with hereditary cancer syndromes and somatic abnormalities in therapy-related cancers.

Major genes associated with hereditary multiple primary cancers:

Gene/syndromeAssociated cancer combinationsPrevalence
MLH1/MSH2/MSH6/PMS2 (Lynch syndrome)Colorectal+endometrial cancer, gastric cancer, ovarian cancer, urinary tract cancer3-5% of colorectal cancers
BRCA1/2Breast+ovarian cancer, male breast+prostate cancer5-10% of breast cancers
TP53 (Li-Fraumeni)Sarcoma+breast cancer+brain tumor+adrenocortical carcinoma+hematologic cancerRare
PTEN (Cowden syndrome)Breast+thyroid+endometrial cancerRare
APC (FAP)Colorectal+duodenal cancer+brain tumor+thyroid cancer<1% of colorectal cancers
RB1Retinoblastoma+osteosarcoma+melanomaRare
VHLKidney cancer+pheochromocytoma+hemangioblastomaRare

Genomics of therapy-related secondary AML/MDS: in alkylating agent-related t-AML, TP53 mutation (>40%), complex karyotype, del(5q) and del(7q) are characteristic. In topoisomerase II inhibitor-related t-AML, 11q23 KMT2A rearrangement is characteristic. Indicators of genomic instability: microsatellite instability (MSI-high) suggests Lynch syndrome-related MPC and predicts responsiveness to immunotherapy (pembrolizumab). Tumor mutational burden (TMB-high) is also used to consider the applicability of immunotherapy in patients with multiple primary cancers. In MPC patients with BRCA1/2 germline variants, it is clinically important to check eligibility for PARP inhibitors (olaparib, niraparib).

4. General epidemiology

Multiple primary cancers are a clinical entity that is gradually increasing along with improved cancer treatment outcomes. Among cancer survivors worldwide, multiple primary cancers account for about 10-16% of all cancer diagnoses, and the risk of second primary cancer rises as cancer survival lengthens. In Korea, according to National Cancer Center Korea Central Cancer Registry data, the proportion of multiple primary cancers among all registered cancers is increasing, from about 4-6% in the 2010s to 8-12% recently.

By cancer type, the incidence of second primary cancer is particularly high among survivors of melanoma, head and neck cancer, breast cancer and colorectal cancer. In survivors of childhood cancer (childhood ALL, lymphoma, Wilms tumor, etc.), the risk of second primary cancer due to radiotherapy and chemotherapy is higher than in adult survivors, because of treatment intensity and remaining life span. Synchronous MPC, in which two or more primary cancers are already identified at diagnosis, accounts for about 30-40% of all MPC, and metachronous MPC is when a second primary cancer develops more than 6 months (usually several years) after the first cancer diagnosis. In Korea, Health Insurance Review & Assessment Service (HIRA) data are used for long-term tracking of second cancer trends in cancer survivors.

5. Pathophysiology

Several mechanisms act independently or in combination in the development of multiple primary cancers.

Common carcinogen exposure (Field cancerization): the concept of 'field cancerization', in which epithelial cells throughout an organ exposed to the same carcinogen for a long time accumulate molecular changes, has explanatory power. Accumulation of molecular damage throughout the mucosa of the oral cavity, pharynx, larynx, esophagus and lung due to smoking is a representative example. Mucosal damage throughout the upper digestive tract due to alcohol shows a similar pattern. Coexistence of HPV-related oropharyngeal cancer and cervical cancer also falls into this category.

Multiple cancer susceptibility due to hereditary predisposition: germline mutations such as BRCA1/2 and MLH1/MSH2 impair DNA damage repair capacity systemically, lowering the threshold at which repeated DNA damage develops into tumors. In Lynch syndrome, microsatellite instability (MSI) accelerates systemic mutation accumulation. Therapy-related carcinogenesis: radiation directly damages the DNA of target cells and generates free radicals, inducing secondary mutations. Alkylating agents cause mutations through DNA alkylation, which is particularly lethal in hematopoietic progenitor cells. Impaired immune surveillance: reduced immune surveillance due to treatment of the first cancer (chemoradiotherapy) or underlying immunodeficiency increases the risk of second primary cancer. Hormonal environment: estrogen exposure partly explains the association between breast cancer and endometrial cancer.

6. Symptoms

In multiple primary cancers, different symptoms appear simultaneously or sequentially according to each affected primary site. Clinically, the most important point is not to mistake a second primary cancer for metastatic cancer.

In synchronous MPC, symptoms related to two or more cancers may be present simultaneously at diagnosis—for example, colorectal cancer (bloody stool, abdominal pain, weight loss) coexisting with lung cancer (cough, hemoptysis). In metachronous MPC, after the symptoms of the first cancer have completely resolved, independent symptoms of the second cancer newly appear after a latency of several years. When new symptoms appear in a cancer survivor judged to be cured long term, the possibility of a second primary cancer should be actively considered. Suspicion of a second primary cancer is especially high when the histologic type differs from the previous cancer or when a new lesion appears at a site different from the usual metastatic pattern of the previous cancer.

In patients with hereditary multiple primary cancers (Lynch syndrome, BRCA variants, etc.), there is typically a family history and multiple cancers arise at a relatively young age. Therapy-related second cancers develop after a latency of several years to about 10 years after the end of the causative treatment and may present as hematologic abnormalities (pancytopenia, leukocytosis) or a new mass within the irradiation field.

7. Signs

The key to MPC diagnosis is proving that a new lesion is an independent primary cancer and not a metastasis. The following international criteria (Warren-Gates criteria as modified by Moertel) are widely applied: ① each tumor must be histopathologically confirmed as a separate malignant tumor; ② one tumor must not be a metastasis or recurrence of the other; ③ in double primary cancer, normal tissue must exist between the two tumors.

Clinical signs suggesting a second primary cancer: a new lesion at a site different from the usual metastatic route of the previous cancer (e.g., a colonic lesion in a patient with a history of prostate cancer → suspect a primary colorectal cancer rather than prostate cancer metastasis). A histologic type fundamentally different from the previous cancer (adenocarcinoma in a patient with a history of squamous cell carcinoma). New tumor marker abnormalities on blood tests (elevation of a marker such as CEA, AFP, PSA or CA-125 that differs from the previous cancer's). Pancytopenia or blasts on complete blood count (suspect therapy-related secondary hematologic cancer). A solitary lesion on imaging inconsistent with the metastatic pattern of the previous cancer.

8. Screening

Screening for second primary cancers in cancer survivors is an important challenge in modern oncology. The National Cancer Center of Korea is laying the groundwork for early detection of second primary cancers through health screening guidelines specialized for cancer survivors.

National cancer screening for the general population: Korea's national cancer screening program (gastric, colorectal, breast, cervical, lung and liver cancer) applies equally to cancer survivors, enabling early detection of synchronous or metachronous second primary cancers.

Enhanced screening for high-risk hereditary MPC groups: Lynch syndrome: colonoscopy (every 1-2 years), endometrial ultrasound/endometrial aspiration biopsy (every 1-2 years), upper endoscopy (every 2 years). BRCA1/2: breast MRI (annually), mammography, ovarian cancer ultrasound+CA-125 (every 6 months, though because efficacy is limited, prophylactic salpingo-oophorectomy is recommended). Tailored screening for survivors of prior cancer treatment: breast cancer screening after radiotherapy for Hodgkin lymphoma (annual breast MRI+mammography starting 8-10 years after chest radiation). Monitoring for thyroid cancer and second brain tumors after radiotherapy for childhood brain tumors. Monitoring for therapy-related AML/MDS after treatment of leukemia and lymphoma (regular complete blood counts). Awareness of increased risk of colorectal, lung and gastric cancer after radiotherapy and chemotherapy for testicular cancer.

9. Diagnosis

MPC diagnosis is the process of proving that a new lesion is a second primary cancer. Histopathologic confirmation is essential. Biopsy of the new lesion confirms the difference in histologic type from the primary cancer, and when needed, differences in molecular profile are established through immunohistochemistry (IHC), FISH and NGS.

Molecular profile comparison: different somatic mutation profiles between two tumors are evidence of independent primary cancers. If the same mutation is present in the same gene, one tumor is likely a metastasis of the other. An NGS panel is applied to both tumors simultaneously to establish clonal relatedness. Lynch syndrome-related MPC is screened by microsatellite instability (MSI) testing and immunohistochemistry (MLH1/MSH2/MSH6/PMS2). Hereditary breast-ovarian cancer syndrome is confirmed by germline BRCA1/2 genetic testing (blood or saliva DNA). Imaging: PET-CT, CT and MRI assess the extent of both lesions, metastatic pattern and the presence of other distant metastases. When a new lesion differs from the usual metastatic pattern of the previous cancer, the possibility of MPC is pursued more actively. ICD-10 coding: C97 is used with the code of each primary site recorded additionally (e.g., C97 + C18.0 + C50.1 → colorectal cancer+breast cancer MPC).

10. Treatment

Treatment of multiple primary cancers is individualized by comprehensively considering the biologic features and stage of each primary cancer, the patient's overall health, and the cumulative toxicity of prior treatment. Which cancer to treat first, and whether to treat them simultaneously or sequentially, is decided by a multidisciplinary team (MDT).

Surgery: when both primary cancers are localized and resectable, the principle is to resect both lesions simultaneously or sequentially, in one operation or in separate operations. E.g., simultaneous laparoscopic surgery for ipsilateral colorectal cancer + kidney cancer. Radiotherapy: the relationship between the previous radiation field and the new lesion must be considered, and re-irradiation is planned cautiously. Systemic therapy: targeted therapy suited to each primary cancer is chosen first. In BRCA1/2 variant carriers, PARP inhibitors (olaparib, niraparib, talazoparib) may be applicable to breast, ovarian, prostate and pancreatic cancer alike. In MSI-H/dMMR tumors, immune checkpoint inhibitors (pembrolizumab) are 'tissue-agnostic approved' drugs applicable regardless of primary site. Immunotherapy is particularly effective in Lynch syndrome-related MPC. To minimize the cumulative effects of treatment toxicity, management such as cardio-oncology and nephrotoxicity is important. Under Korean National Health Insurance, patients with the C97 code receive the special copayment reduction for each corresponding cancer separately, and a multidisciplinary care plan is a coverage requirement.

11. Prognosis

The prognosis of multiple primary cancers is determined by the prognosis and stage of each individual primary cancer and the interactions between them. Overall survival is generally lower than with a single primary cancer, but a favorable prognosis is possible if each cancer is detected early and treated effectively.

Studies show that metachronous MPC tends to have a higher 5-year survival rate than synchronous MPC. This is because in metachronous MPC, the second cancer is often detected early through surveillance programs after the first cancer is cured. In SEER data-based studies, the 5-year relative survival rate of synchronous double primary cancers is about 60-70% of that of single primary cancers, but varies greatly by cancer combination and stage. In Korean National Cancer Center data, the 5-year survival rate for second primary cancers in cancer survivors ranges widely from 20-80% depending on the stage and type of the second cancer. In hereditary MPC (Lynch syndrome, BRCA variants), each cancer tends to be detected relatively early, so the prognosis is not poor, but the risk of continued multiple cancer development remains. Therapy-related secondary hematologic cancers (t-AML/MDS) have a very poor prognosis (5-year OS <20%).

12. Prevention

The key to preventing multiple primary cancers is preventing a second primary cancer after the first cancer. Management of shared risk factors: smoking is a shared risk factor for many cancers, so smoking cessation must be strongly recommended after treatment of the first cancer. Minimizing alcohol intake, maintaining a normal weight and regular physical activity help lower the risk of second primary cancer. Risk-reducing surgery for hereditary MPC: in women with BRCA1/2 variants, prophylactic mastectomy (90% risk reduction) or prophylactic salpingo-oophorectomy (85-90% risk reduction) is performed. In Lynch syndrome, prophylactic hysterectomy and oophorectomy and partial or total colectomy are considered. Chemoprevention: breast cancer chemoprevention with antiestrogens (tamoxifen, raloxifene) is considered in women with BRCA1 variants. In Lynch syndrome, the colorectal cancer risk-reducing effect of aspirin was demonstrated in a clinical trial (CAPP2), and low-dose aspirin is recommended. Gastric cancer prevention by eradication therapy in patients with H. pylori infection. Prevention of HPV-related oropharyngeal and cervical cancer with HPV vaccination. Participation in a regular comprehensive cancer screening program after treatment of the first cancer is the most important practical measure for early detection of second primary cancers and improved treatment outcomes.


13. References

  1. Vogt A, et al. Multiple primary tumors: challenges and approaches. A review. ESMO Open. 2017;2(2):e000172.
  2. Bhatt VR, et al. Risk of subsequent primary malignancies after cancer treatment in childhood. J Natl Cancer Inst. 2018;110(4):400-408.
  3. Lynch HT, et al. Hereditary colorectal cancer syndromes: molecular genetics, genetic counseling, diagnosis, and management. Fam Cancer. 2008;7(1):27-39.
  4. Domchek SM, et al. Association of risk-reducing surgery in BRCA1/2 mutation carriers with cancer risk and mortality. JAMA. 2010;304(9):967-975.
  5. National Cancer Center. Health management guidelines for cancer survivors. National Cancer Center. 2023.
  6. National Cancer Center. Cancer Registration Statistics in Korea, 2022. Ministry of Health and Welfare (MOHW) and National Cancer Center. 2024.
  7. Crocetti E, et al. Multiple primary cancers in an Italian cancer registry. Cancer Causes Control. 2008;19(2):157-164.
  8. Warren S, Gates O. Multiple primary malignant tumors: a survey of the literature and a statistical study. Am J Cancer. 1932;16:1358-1414.
  9. Matesich SM, et al. Second cancer after treatment of breast cancer. Am J Clin Oncol. 2003;26(5):465-471.
  10. Health Insurance Review & Assessment Service. Criteria for applying the special copayment reduction to multiple primary cancers. 2023.